Search | JOV | ARVO Journals

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting

Jose Alain Sahel; Catherine Vignal-Clermont; Valerio Carelli; Chiara La Morgia; Mark L. Moster; Robert C Sergott; Sean P. Donahue; Helene Dollfus; Thomas Klopstock; Rabih Hage; Vasily Smirnov; Catherine Cochard; Francis Munier; Pauline Zoppe; Magali Taiel; Patrick Yu-Wai-Man

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):419.

ARVO Annual Meeting Abstract June 2024

Treatment Options For Acute/Subacute Patients With m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy: A Meta-Analysis

Patrick Yu-Wai-Man; Nancy J. Newman; Valerio Carelli; Valerie Biousse; Catherine Vignal-Clermont; François Montestruc; Magali Taiel; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):416.

ARVO Annual Meeting Abstract June 2023

Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs

Chiara La Morgia; Catherine Vignal-Clermont; Valerio Carelli; Rabih Hage; Mark L. Moster; Robert C Sergott; Sean P Donahue; Patrick Yu-Wai-Man; Hélène Dollfus; Thomas Klopstock; Vasily M. SMIRNOV; Catherine Cochard; Claudia Prospero Ponce; Francis Munier; Magali Taiel; Jose Sahel

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1956.

ARVO Annual Meeting Abstract June 2023

Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4 -LHON patients: the RESTORE study

Patrick Yu-Wai-Man; Nancy J Newman; Biousse Valérie; Valerio Carelli; Mark L. Moster; Catherine Vignal-Clermont; Thomas Klopstock; Alfredo A. Sadun; Robert C Sergott; Magali Taiel; José-Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1955.

ARVO Annual Meeting Abstract June 2023

Biomarkers of inflammation detected in Leber Hereditary Optic Neuropathy using phase contrast AOSLO

Elena Gofas; Nathaniel Norberg; Michel Paques; Kate grieve; Catherine Vignal Clermont

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4336.

ARVO Annual Meeting Abstract June 2023

Leber Hereditary Optic Neuropathy (LHON): Online medical education can significantly improve physicians’ diagnostic competence and confidence, and improve therapy knowledge

Siggi Trier; Gillian Griffith; Karen Reid; Patrick Yu-Wai-Man; Valerio Carelli; Thomas Klopstock; Bart Peter Leroy; Nancy J Newman; Catherine Vignal-Clermont

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4079.

ARVO Annual Meeting Abstract June 2022

The phase III REFLECT trial: efficacy of bilateral gene therapy for Leber hereditary optic neuropathy (LHON) is maintained 2 years post administration

Patrick Yu-Wai-Man; Nancy Newman; Prem S Subramanian; Mark Moster; An-Guor Wang; Sean Donahue; Bart Leroy; Valerio Carelli; Valerie Biousse; Catherine Vignal-Clermont; Alfredo A Sadun; Gema Fernandez; Elizabeth Fortin; Rudrani Banik; Magali Taiel; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):434.

ARVO Annual Meeting Abstract June 2022

Detecting inflammatory cells in patients with Multiple Sclerosis using AO-SLO phase contrast imaging

Elena Gofas; Celine Louapre; Nathaniel Norberg; Ysoline Beigneux; Michel Paques; Catherine Vignal Clermont; Kate Grieve

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2690.

ARVO Annual Meeting Abstract June 2021

Evaluation of the efficacy of rAAV2/2- ND4 gene therapy for Leber hereditary optic neuropathy compared with the natural history

Patrick Yu-Wai-Man; Nancy J Newman; Valerio Carelli; Mark Moster; Catherine Vignal-Clermont; Alfredo A Sadun; Chiara La Morgia; Francesco Bandello; Lorena Castillo Campillo; Stephanie Leruez; Dean Cestari; Robert Foroozan; Rustum Karanjia; Laure Blouin; Magali Taiel; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2676.

ARVO Annual Meeting Abstract June 2020

Bilateral Visual Improvement with Unilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)

Patrick Yu-Wai-Man; Nancy J Newman; Valerio Carelli; Valerie Biousse; Alfredo A. Sadun; Mark L Moster; Catherine Vignal-Clermont; Robert C Sergott; Thomas Klopstock klopstock; Laure Blouin; Magali Taiel; Pierre Burguière; Caroline Chevalier; Barrett Katz; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):5181.

ARVO Annual Meeting Abstract July 2019

rAAV2/2- ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): 72-Week Data from the REVERSE Phase III Clinical Trial

Patrick Yu-Wai-Man; Mark Moster; Alfredo A Sadun; Thomas Klopstock; Catherine Vignal-Clermont; Nancy J Newman; Robert C Sergott; Valerio Carelli; Caroline Chevalier; Laure Blouin; Magali Taiel; Barrett Katz; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4806.

ARVO Annual Meeting Abstract July 2018

Visual Acuity and Safety Outcomes 2.5 Years Post-Treatment with rAAV2/2- ND4 , an Investigational Gene Therapy for ND4 LHON: Results of a Phase I/II Trial

Jose A. Sahel; Barrett Katz; Catherine Vignal-Clermont; Laure Blouin

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4530.

ARVO Annual Meeting Abstract July 2018

Intravitreal injection of rAAV2/2- ND4 in LHON: absence of correlation between ocular inflammation and humoral or cellular immune responses to AAV2

Barrett Katz; Anne Galy; Serge Fitoussi; Catherine Vignal Clermont; Jose A. Sahel; Catherine Cancian; Nitza Thomasson; Celine BOUQUET

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4531.

ARVO Annual Meeting Abstract June 2017

Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE Clinical Gene Therapy Trials

Patrick Yu-Wai-Man; Nancy J Newman; Robert Sergott; Molly Scannell Bryan; Valerio Carelli; Thomas Klopstock; Mark Moster; Alfredo A. Sadun; Jose Alain Sahel; Catherine Vignal; Scott Uretsky

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3865.

ARVO Annual Meeting Abstract June 2017

Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2- ND4, an Investigational Gene Therapy for ND4 LHON

Scott Uretsky; Nitza Thomasson; Celine BOUQUET; Anne Galy; Jean Philppe Combal; Serge Fitoussi; Jose Alain Sahel; Catherine Vignal

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4681.

ARVO Annual Meeting Abstract September 2016

Intravitreal injection of rAAV2/2– ND4 (GS010): immune responses and ocular inflammation in non-human primates and patients with Leber Hereditary Optic Neuropathy (LHON)

Nitza Thomasson; Celine Bouquet; Anne Galy; Serge Fitoussi; Sandrine Meunier; Scott Uretsky; Catherine Vignal; Jose Sahel; Jean Philppe Combal

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1177.

ARVO Annual Meeting Abstract June 2015

Preliminary safety and tolerability results of intravitreal administration of GS010, a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing human wildtype mitochondrial NADH dehydrogenase 4 ( ND4 ) gene in patients with Leber Hereditary Optic Neuropathy (LHON) due to the G11778A ND4 mitochondrial DNA mutation

Jose Alain Sahel; Scott Uretsky; Jean Philppe Combal; Anne Galy; Nitza Thomasson; Serge Fitoussi; Marisol Corral-Debrinsky; Geraldine Honnet; Catherine Vignal

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1088.

ARVO Annual Meeting Abstract April 2014

Phenotypic features related to Wolfram syndrome in 17 families

Stephanie Leruez; Verschoore Marion; Johanna Grenier; Xavier Zanlonghi; Christian P Hamel; Christophe Orssaud; Catherine Vignal-Clermont; Vincent Pascal Procaccio Reynier; Patrizia Dominique Bonneau; Dan Milea

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6423.

ARVO Annual Meeting Abstract June 2013

Inner nuclear layer microcystic changes in optic nerve atrophy: a prospective study

Benjamin Wolff; Vivien Vasseur; Chrysanthi Basdekidou; Jose Sahel; Catherine Vignal; Martine Mauget-Faÿsse

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):6347.

Vision Sciences Society Annual Meeting Abstract September 2011

Detection and categorization abilities following peripheral or cerebral visual impairment

Celine Cavezian; Isabelle Gaudry; Anne-claire Viret; Olivier Coubard; Carole Peyrin; Catherine Vignal; Olivier Gout; Sylvie Chokron

Journal of Vision. 2011; 11(11):1123. https://doi.org/10.1167/11.11.1123

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Specify Date Range

Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy in the Real-Life Setting

Treatment Options For Acute/Subacute Patients With m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy: A Meta-Analysis

Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs

Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4 -LHON patients: the RESTORE study

Biomarkers of inflammation detected in Leber Hereditary Optic Neuropathy using phase contrast AOSLO

Leber Hereditary Optic Neuropathy (LHON): Online medical education can significantly improve physicians’ diagnostic competence and confidence, and improve therapy knowledge

The phase III REFLECT trial: efficacy of bilateral gene therapy for Leber hereditary optic neuropathy (LHON) is maintained 2 years post administration

Detecting inflammatory cells in patients with Multiple Sclerosis using AO-SLO phase contrast imaging

Evaluation of the efficacy of rAAV2/2- ND4 gene therapy for Leber hereditary optic neuropathy compared with the natural history

Bilateral Visual Improvement with Unilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)

rAAV2/2- ND4 for the Treatment of Leber Hereditary Optic Neuropathy (LHON): 72-Week Data from the REVERSE Phase III Clinical Trial

Visual Acuity and Safety Outcomes 2.5 Years Post-Treatment with rAAV2/2- ND4 , an Investigational Gene Therapy for ND4 LHON: Results of a Phase I/II Trial

Intravitreal injection of rAAV2/2- ND4 in LHON: absence of correlation between ocular inflammation and humoral or cellular immune responses to AAV2

Preliminary Baseline Characteristics of Patients with Leber Hereditary Optic Neuropathy (LHON) Enrolled in the RESCUE and REVERSE Clinical Gene Therapy Trials

Phase I/IIa Visual Acuity Outcomes 1.5-Years Post-Treatment with rAAV2/2- ND4, an Investigational Gene Therapy for ND4 LHON

Intravitreal injection of rAAV2/2– ND4 (GS010): immune responses and ocular inflammation in non-human primates and patients with Leber Hereditary Optic Neuropathy (LHON)

Phenotypic features related to Wolfram syndrome in 17 families

Inner nuclear layer microcystic changes in optic nerve atrophy: a prospective study

Detection and categorization abilities following peripheral or cerebral visual impairment

To View More...

You must be signed into an individual account to use this feature.